Ipsen's Stock Climbs 2.5% and Targets €170 Following New Acquisition
The biopharmaceutical company stands out in the late Paris session, continuing an upward trend that started several weeks ago. The stock is testing a major technical threshold, following the announcement of a new external growth operation in rare diseases.
The Stock Briefly Breaks Through its €170.80 Resistance During the Session
Ipsen's stock rose 2.47% to €169.90, within a CAC 40 up by 0.44%. The stock even surpassed its resistance of €170.80 during the session, reaching a high of €172.40, before falling back below. The company is performing well above its three moving averages, with a nearly 20% gap from its MM200 (€141.62), indicating the strength of the underlying trend. The RSI at 65 is approaching the overbought zone without entering it, while the MACD remains oriented upwards. Over one year, the stock has gained 61.9%, supported by a 10.3% increase over the past month alone.
Second Acquisition in Three Days Bolsters Portfolio in Rare Diseases
This move follows the acquisition of Memo Therapeutics, announced on July 1st. The deal involves potravitug, a monoclonal antibody in Phase II targeting the BK polyomavirus in kidney transplant patients. The initial payment is €200 million, with additional payments linked to development milestones and commercial performance potentially bringing the total compensation beyond €700 million. The completion is expected in the third quarter of 2026. This purchase closely follows that of Kartos Therapeutics, announced on June 29th for an initial amount of $450 million, targeting myelofibrosis. Regarding analyst opinions, Kepler Cheuvreux maintained a 'hold' rating on July 1st with a target of €132, now significantly below the current market price. The maintenance of the €170.80 threshold will be the next technical reference point after today's intraday test.
